XML 14 R4.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Interim Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Millions
Mar. 31, 2024
Dec. 31, 2023
Current assets:    
Cash and cash equivalents $ 746 $ 1,203
Restricted cash and restricted cash equivalents 607 604
Accounts and notes receivable, net 792 610
Inventories 1,391 1,352
Prepaid expenses and other 61 66
Total current assets 3,597 3,835
Property, plant, and equipment 9,469 9,412
Less: Accumulated depreciation (6,260) (6,196)
Property, plant, and equipment, net 3,209 3,216
Operating lease right-of-use assets 252 260
Goodwill 102 102
Other intangible assets, net 3 3
Investments in affiliates 165 158
Other assets 650 677
Total assets 7,978 8,251
Current liabilities:    
Accounts payable 963 1,159
Compensation and other employee-related cost 79 89
Short-term and current maturities of long-term debt 41 51
Current environmental remediation 129 129
Other accrued liabilities 1,019 1,058
Total current liabilities 2,231 2,486
Long-term debt, net 3,968 3,987
Operating lease liabilities 198 206
Long-term environmental remediation 452 461
Deferred income taxes 44 44
Other liabilities 331 328
Total liabilities 7,224 7,512
Commitments and contingent liabilities
Equity    
Common stock (par value $0.01 per share; 810,000,000 shares authorized; 197,711,836 shares issued and 148,779,449 shares outstanding at March 31, 2024; 197,519,784 shares issued and 148,587,397 shares outstanding at December 31, 2023) 2 2
Treasury stock, at cost (48,932,387 shares at March 31, 2024 and December 31, 2023) (1,806) (1,806)
Additional paid-in capital 1,033 1,033
Retained earnings 1,797 1,782
Accumulated other comprehensive loss (274) (274)
Total Chemours stockholders’ equity 752 737
Non-controlling interests 2 2
Total equity 754 739
Total liabilities and equity $ 7,978 $ 8,251